These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34290356)

  • 1. 3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity.
    Gopal S; Kwon SJ; Ku B; Lee DW; Kim J; Dordick JS
    Commun Biol; 2021 Jul; 4(1):893. PubMed ID: 34290356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery.
    Sturniolo I; Váróczy C; Bede ÁM; Hegedűs C; Demény MÁ; Virág L
    J Vis Exp; 2024 Apr; (206):. PubMed ID: 38738886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
    Miura D; Yoneyama K; Furuhata Y; Shimizu K
    J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
    Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
    Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
    Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
    Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
    Collins DM; O'Donovan N; McGowan PM; O'Sullivan F; Duffy MJ; Crown J
    Ann Oncol; 2012 Jul; 23(7):1788-95. PubMed ID: 22056974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
    Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
    J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.
    Zhou Q; Gil-Krzewska A; Peruzzi G; Borrego F
    Clin Exp Immunol; 2013 Jul; 173(1):131-9. PubMed ID: 23607800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
    Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
    Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
    Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
    Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
    Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
    Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.